Truist Securities Maintains Buy on Abivax, Raises Price Target to $155
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ: ABVX ) with a Buy and raises the price target from $135 to $155.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.